 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...224225226227228229230231232233234235236» |
- Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, Metastases: A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients (clinicaltrials.gov) - Aug 28, 2012
P1, N=45, Active, not recruiting, Sponsor: University of Chicago
N=20 --> 45
- | Erbitux (cetuximab) / Eli Lilly
New P2 trial, Surgery, Metastases: ECKINOXE: Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer (clinicaltrials.gov) - Aug 28, 2012
P2, N=186, Not yet recruiting, Sponsor: Assistance Publique - H
- New P2 trial: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis (clinicaltrials.gov) - Aug 26, 2012
P2, N=65, Suspended, Sponsor: Federation Francophone de Cancerologie Digestive
- |||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, HEOR, Combination therapy, Metastases: AFEQT: Colorectal Cancer Metastatic (clinicaltrials.gov) - Aug 22, 2012
P3, N=200, Recruiting, Sponsor: Sanofi
N=20 --> 45 Not yet recruiting --> Recruiting
- | LY2090314 / Eli Lilly
New P1/2 trial, Metastases, Biopsy: LY2090314 With Gemcitabine Hydrochloride or FOLFOX Combination Chemotherapy in Treating Patients With Untreated, Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 21, 2012
P1/2, N=40, Not yet recruiting, Sponsor: Mayo Clinic
- |||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open, Metastases: AFLAME: A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy (clinicaltrials.gov) - Aug 21, 2012
P3, N=330, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial completion: Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 21, 2012
P2, N=68, Completed, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Active, not recruiting --> Recruiting Recruiting --> Completed
- semaxanib (SU5416) / Pfizer
Trial completion, Metastases: Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 21, 2012
P3, N=0, Completed, Sponsor: Pfizer
Recruiting --> Completed Active, not recruiting --> Completed
- ganitumab (AMG 479) / Takeda, ImmunityBio
Trial initiation date, Metastases: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 20, 2012
P2, N=0, Withdrawn, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Initiation date: Jan 2012 --> Aug 2012
- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
New P3 trial, HEOR, Combination therapy, Metastases: AFEQT: Colorectal Cancer Metastatic (clinicaltrials.gov) - Aug 20, 2012
P3, N=200, Recruiting, Sponsor: Sanofi
- ||| Vectibix (panitumumab) / Amgen, motesanib (AMG 706) / Takeda
Trial completion: Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 20, 2012
P1, N=119, Completed, Sponsor: Amgen
Initiation date: Jan 2012 --> Aug 2012 Active, not recruiting --> Completed
- | Tasigna (nilotinib) / Novartis, Inhibikase
New P2 trial: Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Aug 19, 2012
P2, N=44, Recruiting, Sponsor: Mayo Clinic
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 17, 2012
P2, N=100, Recruiting, Sponsor: Chinese Academy of Medical Sciences
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma (clinicaltrials.gov) - Aug 16, 2012
P2, N=80, Not yet recruiting, Sponsor: HaEmek Medical Center, Israel
- Enrollment open: FOLFIRINOX + RT for Pancreatic Cancer (clinicaltrials.gov) - Aug 16, 2012
P2, N=50, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment change, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Aug 15, 2012
P1, N=20, Recruiting, Sponsor: Oncolytics Biotech
Not yet recruiting --> Recruiting N=12 --> 20
- | Enrollment change, Metastases: FLOT4: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Aug 14, 2012
P2/3, N=590, Recruiting, Sponsor: Krankenhaus Nordwest
N=12 --> 20 N=300 --> 590
- 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 14, 2012
P2, N=43, Recruiting, Sponsor: Case Comprehensive Cancer Center
- |||||||||| onartuzumab (RG3638) / Roche
New P3 trial, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Aug 8, 2012
P3, N=800, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment change, Metastases: NAPOLI-1: Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 7, 2012
P3, N=405, Active, not recruiting, Sponsor: Merrimack Pharmaceuticals
N=300 --> 590 N=270 --> 405
- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
New P3 trial, Metastases: AFLAME: A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy (clinicaltrials.gov) - Aug 7, 2012
P3, N=330, Recruiting, Sponsor: Sanofi
- New P2 trial: A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients (clinicaltrials.gov) - Aug 7, 2012
P2, N=31, Recruiting, Sponsor: University of Michigan Cancer Center
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Surgery, Post-surgery: A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 7, 2012
P2, N=21, Recruiting, Sponsor: NorthShore University HealthSystem
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy and FOLFOX Chemotherapy for Rectal Cancer (clinicaltrials.gov) - Aug 5, 2012
P2, N=40, Recruiting, Sponsor: Beth Israel Medical Center
- ||||||| Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Surgery: AVANT: Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer (clinicaltrials.gov) - Aug 5, 2012
P3, N=3451, Completed, Sponsor: Hoffmann-La Roche
N=270 --> 405 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients (clinicaltrials.gov) - Aug 2, 2012
P2, N=72, Active, not recruiting, Sponsor: Fudan University
- ||| AL101 / Ayala Pharma
New P1 trial, Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Jul 29, 2012
P1, N=60, Recruiting, Sponsor: Bristol-Myers Squibb
- New P2 trial, Metastases: Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jul 26, 2012
P2, N=42, Recruiting, Sponsor: University of Florida
- ||||| duligotuzumab (MEHD7945A) / Roche
New P2 trial, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jul 26, 2012
P2, N=135, Active, not recruiting, Sponsor: Genentech
- ||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial, Metastases: Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer (clinicaltrials.gov) - Jul 25, 2012
P2, N=70, Recruiting, Sponsor: Richard Goldberg
- Trial initiation date: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Jul 23, 2012
P=N/A, N=42, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Initiation date: Jan 2012 --> Jun 2012
- | dactinomycin / Generic mfg.
Enrollment open: Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia (clinicaltrials.gov) - Jul 23, 2012
P3, N=384, Recruiting, Sponsor: Gynecologic Oncology Group
Initiation date: Jan 2012 --> Jun 2012 Not yet recruiting --> Recruiting
- Enrollment open: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Jul 23, 2012
P=N/A, N=42, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | leucovorin calcium / Generic mfg., tegafur/uracil / Generic mfg., capecitabine / Generic mfg.
Trial completion, Metastases: COLOCROSS: Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 19, 2012
P3, N=89, Completed, Sponsor: Centre Oscar Lambret
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Combination therapy, Metastases: VELOUR: Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen (clinicaltrials.gov) - Jul 19, 2012
P3, N=1226, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment change, Combination therapy, Metastases: Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 18, 2012
P1, N=16, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed N=22 --> 16
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2/3 trial: BOS3: Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases (clinicaltrials.gov) - Jul 18, 2012
P2/3, N=240, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- | Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Surgery: NCCTG N0147: Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer (clinicaltrials.gov) - Jul 18, 2012
P3, N=3768, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=22 --> 16 Completed --> Active, not recruiting
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Combination therapy, Metastases: Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 18, 2012
P1, N=16, Completed, Sponsor: Sanofi
Completed --> Active, not recruiting Active, not recruiting --> Completed
- | New P2 trial, Surgery, Metastases: Comparison of chemotherapy with radiochemotherapy as treatment of patients with pancreatic carcinoma, which cannot be removed by surgery (EUDRACT) - Jul 17, 2012
P2, N=68, Ongoing, Sponsor: Med. Uni Wien, Abteilung f. Innere Medizin I, Onkologie
- || Enrollment closed: AALL02P2: Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes (clinicaltrials.gov) - Jul 17, 2012
P=N/A, N=168, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- ||||| leucovorin calcium / Generic mfg., thioguanine / Generic mfg.
Enrollment closed: AALL0232: Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 17, 2012
P3, N=3154, Active, not recruiting, Sponsor: Children's Oncology Group
Suspended --> Active, not recruiting Suspended --> Active, not recruiting
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
New P1 trial, Metastases: Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies (clinicaltrials.gov) - Jul 16, 2012
P1, N=45, Recruiting, Sponsor: University of Chicago
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Metastases: Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients (clinicaltrials.gov) - Jul 15, 2012
P4, N=1500, Active, not recruiting, Sponsor: Asan Medical Center
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- || 5-fluorouracil / Generic mfg., irinotecan / Generic mfg.
New P3 trial: ITACA-S: Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (clinicaltrials.gov) - Jul 12, 2012
P3, N=1100, Completed, Sponsor: Mario Negri Institute for Pharmacological Research
- |||||||||| Avastin (bevacizumab) / Roche
New P3 trial, Metastases: VISNU-1: Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (clinicaltrials.gov) - Jul 11, 2012
P3, N=350, Recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
- ||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P2 trial, Circulating tumor cells, Tumor cell, Metastases: VISNU-2: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (clinicaltrials.gov) - Jul 11, 2012
P2, N=240, Recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
- Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Colorectal Cancer (clinicaltrials.gov) - Jul 11, 2012
P2, N=0, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, New P2 trial, Metastases: Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1 (clinicaltrials.gov) - Jul 10, 2012
P2, N=96, Recruiting, Sponsor: Fundaci
- | Cyramza (ramucirumab) / Eli Lilly
New P2 trial, Combination therapy, Metastases: A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI (clinicaltrials.gov) - Jul 4, 2012
P2, N=30, Active, not recruiting, Sponsor: Eli Lilly and Company